| |
G1 (n = 519)
|
G2 (n = 813)
|
G3 (n = 1554)
|
G4 (n = 576)
|
p-value
|
|---|
|
Severity of myocardial infarction
|
|
Number of coronary vesssels affected ±SD
|
1.99 ± 0.8
|
1.94 ± 0.8
|
1.91 ± 0.8
|
1.84 ± 0.8
|
0.09
|
|
Cardiogenic shock (%)
|
12.1
|
13.1
|
12.0
|
12.4
|
0.8
|
|
Prehospital CPR (%)
|
10.9
|
11.3
|
10.8
|
10.3
|
0.5
|
|
Subacute MI(%) a
|
19.3
|
23.9
|
20.5
|
19.9
|
0.8
|
|
Mean peak CK (U/l) ± SD
|
1599 ± 1679
|
1838 ± 2019
|
1913 ± 2188
|
2025 ± 2167
|
<0.01
|
|
Peak CK > 3000 U/l (%)
|
13.7
|
20.5
|
20.9
|
23.3
|
<0.01
|
|
Post AMI LVEF in % ± SD
|
49.6 ± 9
|
48.9 ± 10
|
48.4 ± 11
|
47.5 ± 10
|
<0.01
|
|
LVEF <40% (%)
|
10.4
|
13.8
|
15.8
|
16.3
|
0.01
|
|
Treatment modalitites
|
|
Primary PCI (%)
|
89.0
|
91.1
|
89.9
|
90.9
|
0.9
|
|
CABG (%)
|
6.1
|
3.9
|
4.8
|
3.4
|
0.14
|
|
Conservative therapy regimen (%)
|
4.8
|
4.9
|
5.2
|
5.7
|
0.8
|
|
Door to balloon time in min (median ± SD)
|
48 ± 32
|
43 ± 44.5
|
46 ± 40
|
44 ± 41
|
0.74
|
|
GP2b3a-Inhibitors (%)
|
70
|
67
|
66
|
70
|
0.7
|
|
ASA (at discharge) (%)
|
94
|
96
|
94
|
95
|
0.64
|
|
ADP-Antagon. (ad) (%)
|
90
|
90.5
|
90
|
94
|
0.23
|
|
Beta-blockers (ad) (%)
|
83
|
84
|
80
|
84
|
0.25
|
|
Statins (ad) (%)
|
86
|
87
|
87
|
86
|
0.9
|
|
ACE/ATR-Inhibitors (ad) (%)
|
77
|
80
|
79
|
79
|
0.9
|
|
Outcome
|
|
Mortality <72 h (%)
|
3.9
|
3.6
|
3.9
|
4.2
|
0.71
|
|
Inhospital mortality (%)
|
8.8
|
7.6
|
7.9
|
8.1
|
0.71
|
|
1-year-mortality (%)
|
15.7
|
15.1
|
14.9
|
16.3
|
0.9
|
|
1-year-MACCE (%)
|
19.2
|
19.5
|
19.1
|
20.4
|
0.8
|
|
5-year-mortality (%)
|
23.9
|
27.7
|
25.7
|
28.3
|
0.46
|
|
5-year-MACCE (%)
|
30.8
|
35.7
|
36.0
|
41.1
|
0.02
|
-
asubacute MI was defined as onset of symptoms >12 h before admission to PCI- center and/or signs of subacute STEMI in initial ECG
